Phenindamine Description
Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures. Structure
Structure for HMDB15556 (Phenindamine)
Synonyms
Value Source NolahistChEMBL ThephorinChEMBL PhenindiamineHMDB Allphar brand OF phenindamine tartrateMeSH Phenindamine tartrateMeSH Carnrick brand OF phenindamine tartrateMeSH Phenindamine hydrochlorideMeSH
Chemical Formlia
C19H19N Average Molecliar Weight
261.3609 Monoisotopic Molecliar Weight
261.151749613 IUPAC Name
2-methyl-9-phenyl-1H,2H,3H,4H,9H-indeno[2,1-c]pyridine Traditional Name
phenindamine CAS Registry Number
82-88-2 SMILES
InChI Identifier
InChI Key
ISFHAYSTHMVOJR-UHFFFAOYSA-N Chemical Taxonomy Description
This compound belongs to the class of organic compounds known as indenes and isoindenes. These are compounds containing an indene moiety(which consists of a cyclopentadiene fused to a benzene ring), or a isoindene moiety (which consists of a cyclopentadiene fused to cyclohexadiene ring). Kingdom
Organic compounds Super Class
Benzenoids Class
Indenes and isoindenes Sub Class
Not Available Direct Parent
Indenes and isoindenes Alternative Parents
Substituents
Molecliar Framework
Aromatic heteropolycyclic compounds External Descriptors
Ontology Status
Expected but not Quantified Origin
Biofunction
Application
Cellliar locations
Physical Properties State
Solid Experimental Properties
Property Value Reference Melting Point91 °CNot Available Boiling PointNot AvailableNot Available Water Solubility2.77e-02 g/LNot Available LogPNot AvailableNot Available
Predicted Properties
Property Value Source Water Solubility0.028 mg/mLALOGPS logP4.04ALOGPS logP3.62ChemAxon logS-4ALOGPS pKa (Strongest Acidic)18.01ChemAxon pKa (Strongest Basic)9ChemAxon Physiological Charge1ChemAxon Hydrogen Acceptor Count1ChemAxon Hydrogen Donor Count0ChemAxon Polar Surface Area3.24 Å2ChemAxon Rotatable Bond Count1ChemAxon Refractivity85.03 m3·mol-1ChemAxon Polarizability31.13 Å3ChemAxon Number of Rings4ChemAxon Bioavailability1ChemAxon Rlie of FiveYesChemAxon Ghose FilterYesChemAxon Vebers RlieYesChemAxon MDDR-like RlieYesChemAxon
Spectra Spectra
Spectrum Type Description Splash Key Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available MS
Mass Spectrum (Electron Ionization)splash10-03di-4490000000-4842a14b86b472cf0ceeView in MoNA
Biological Properties Cellliar Locations
Biofluid Locations
Tissue Location
Not Available Pathways
Not Available Normal Concentrations
Biofluid Status Value Age Sex Condition Reference Details BloodExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01619details UrineExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01619
details
Abnormal Concentrations
Not Available Predicted Concentrations
Biofluid Value Original age Original sex Original condition Comments Blood0-4 uMAdlit (>18 years old)BothNormalPredicted based on drug qualities Blood0-2 umol/mmol creatinineAdlit (>18 years old)BothNormalPredicted based on drug qualities
Associated Disorders and Diseases Disease References
None Associated OMIM IDs
None External Links DrugBank ID
DB01619 DrugBank Metabolite ID
Not Available Phenol Explorer Compound ID
Not Available Phenol Explorer Metabolite ID
Not Available FoodDB ID
Not Available KNApSAcK ID
Not Available Chemspider ID
10817 KEGG Compound ID
C07790 BioCyc ID
Not Available BiGG ID
Not Available Wikipedia Link
Not Available NuGOwiki Link
HMDB15556 Metagene Link
HMDB15556 METLIN ID
Not Available PubChem Compound
11291 PDB ID
Not Available ChEBI ID
130096
Product: Reboxetine (mesylate)
References Synthesis Reference Not Available Material Safety Data Sheet (MSDS) Not Available General References Not AvailableEnzymes
- General function:
- Involved in G-protein coupled receptor protein signaling pathway
- Specific function:
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system
- Gene Name:
- HRH1
- Uniprot ID:
- P35367
- Molecular weight:
- 55783.6
References
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
- ter Laak AM, Venhorst J, Donne-Op den Kelder GM, Timmerman H: The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60. [PubMed:7650688 ]
- Witek TJ Jr, Canestrari DA, Miller RD, Yang JY, Riker DK: The effects of phenindamine tartrate on sleepiness and psychomotor performance. J Allergy Clin Immunol. 1992 Dec;90(6 Pt 1):953-61. [PubMed:1360991 ]
- van Drooge MJ, Donne-op den Kelder GM, Timmerman H: The histamine H1-receptor antagonist binding site. Part I: Active conformation of cyproheptadine. J Comput Aided Mol Des. 1991 Aug;5(4):357-70. [PubMed:1686618 ]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]